Thus, pharmacological modulation of iRHOM2 by targeting two stress-response proteins, K16 and ADAM17, could provide a specific therapeutic strategy in the treatment of PPK's, inflammatory epithelial disease and neoplasia. The gene discussed is RHBDF2; the disease is neoplasm.